| Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds (NCT06134843) | Hobart W. Harris | 2024-09-01 |
| Phase 1/2a to Assess the Safety and Tolerability of TP-122A for the Treatment of Ventilator-Associated Pneumonia (NCT06370598) | Technophage, SA | 2024-09-01 |
| Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer (NCT06574763) | Sun Yat-sen University | 2024-09-01 |
| Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. (NCT06563778) | Chinese PLA General Hospital | 2024-09-01 |
| MRG-001 in Patients With Alcoholic Hepatitis (NCT06307522) | MedRegen LLC | 2024-09-01 |
| First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma (NCT05188859) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-09-01 |
| Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction (NCT06464913) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-09-01 |
| Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer. (NCT07044921) | Chinese PLA General Hospital | 2024-09-01 |
| Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients (NCT05860244) | Assistance Publique - Hôpitaux de Paris | 2024-09-01 |
| The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. (NCT06295094) | Odense University Hospital | 2024-09-01 |
| Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL (NCT06573151) | Ruijin Hospital | 2024-09-01 |
| Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata (NCT06104839) | NEXTGEN Bioscience | 2024-09-01 |
| Cannabidiol's Role in Dementia Management (NCT06514066) | Hospital Pengajar Universiti Putra Malaysia | 2024-09-01 |
| Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer (NCT06513455) | Harbin Medical University | 2024-09-01 |
| Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics (NCT06268964) | Universidad de Colima | 2024-09-01 |
| CelAgace™ OraRinse Solution for Treatment of Candidiasis (NCT03250923) | CelaCare Technologies, Inc. | 2024-09-01 |
| Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy (NCT06880029) | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. | 2024-09-01 |
| Extending the Reach of Evidence-based Practices to Support Student's Attention and Behavior Through Technology (NCT06886217) | San Diego State University | 2024-09-01 |
| Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors (NCT06584006) | The First Affiliated Hospital of Xiamen University | 2024-09-01 |
| A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors (NCT06992687) | Shanghai Huaota Biopharmaceutical Co., Ltd. | 2024-09-01 |
| Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer (NCT06603376) | Shanghai Changzheng Hospital | 2024-09-01 |
| Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL (NCT06573138) | Ruijin Hospital | 2024-09-01 |
| Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens (NCT06572319) | Zhejiang Cancer Hospital | 2024-09-01 |
| T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer (NCT06548178) | Fudan University | 2024-09-01 |
| Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus (NCT06356740) | Hospices Civils de Lyon | 2024-09-01 |
| Software as a Medical Device for the Treatment of Patients With PTSD (NCT06589505) | Otsuka Medical Devices Co., Ltd. Japan | 2024-09-01 |
| Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma (NCT06157099) | OHSU Knight Cancer Institute | 2024-09-01 |
| Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression (NCT06560528) | Tianjin Medical University Cancer Institute and Hospital | 2024-09-01 |
| Prophylactic Antibiotic in Subtalar Fusion Surgery (NCT06527989) | Assiut University | 2024-09-01 |
| A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome (NCT06595797) | Fujian Shengdi Pharmaceutical Co., Ltd. | 2024-09-01 |
| Dapagliflozin to Prevent Anthracycline-Induced Cardiotoxicity (NCT06888505) | Hawler Medical University | 2024-09-01 |
| Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease (NCT06435858) | Cantonal Hospital Graubuenden | 2024-09-01 |
| Tolerability of MDMA in Schizophrenia (NCT05770375) | Anya Bershad, MD, PhD | 2024-09-01 |
| Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy (NCT06553157) | Minia University | 2024-09-01 |
| Efficacy and Safety of FMT for the Treatment of IBS-D and Mental Health Comorbidity in Young Adults (NCT06297421) | Shenzhen Hospital of Southern Medical University | 2024-09-01 |
| A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors (NCT06150885) | Ever Supreme Bio Technology Co., Ltd. | 2024-09-01 |
| Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer (NCT06552858) | Fudan University | 2024-09-01 |
| Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer (NCT05741164) | Emory University | 2024-09-01 |
| Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC (NCT06467799) | Sun Yat-sen University | 2024-09-01 |
| Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity (NCT06296082) | Universiteit Antwerpen | 2024-09-01 |
| Perioperative Immunotherapy for NSCLC (ECTOP-1030) (NCT06572722) | Fudan University | 2024-09-01 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy (NCT06612775) | Shanghai Zhimeng Biopharma, Inc. | 2024-09-01 |
| Lentiviral Gene Therapy for Epilepsy (NCT04601974) | University College, London | 2024-09-01 |
| Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC (NCT06573398) | Ruijin Hospital | 2024-09-01 |
| Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma. (NCT06574412) | The First Hospital of Jilin University | 2024-09-01 |
| Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma (NCT06466434) | M.D. Anderson Cancer Center | 2024-09-01 |
| Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma (NCT06871007) | St. Petersburg State Pavlov Medical University | 2024-09-01 |
| Hypofractionated Online Adaptive Radiotherapy of Breast Cancer (NCT06568705) | Peking Union Medical College Hospital | 2024-09-01 |
| Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study (NCT07047560) | Tianjin Medical University Cancer Institute and Hospital | 2024-09-01 |
| Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts (NCT07307131) | Benha University | 2024-09-01 |
| The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritus. (NCT06579066) | Ain Shams University | 2024-09-01 |
| A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma (NCT06556199) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-08-31 |
| Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients (NCT06544460) | Fudan University | 2024-08-31 |
| A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma (NCT06554561) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-08-31 |
| Skincubator, a Novel Incubator for Skin to Skin Contact Feasibility Study (NCT06543433) | Itamar Nitzan | 2024-08-31 |
| A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. (NCT06116136) | Servier Bio-Innovation LLC | 2024-08-31 |
| Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant (NCT06337331) | Northside Hospital, Inc. | 2024-08-31 |
| Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients (NCT06577961) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-08-31 |
| A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma (NCT06554600) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2024-08-31 |
| Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (NCT06343792) | ReAlta Life Sciences, Inc. | 2024-08-31 |
| Single High-dose Brachytherapy for Giant Osteosarcoma Masses (NCT06524778) | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | 2024-08-30 |
| A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) (NCT06503731) | argenx | 2024-08-30 |
| Short-Term Outcome of Medical Vs. Surgical Management Of Chronic Anal Fissure (NCT06617026) | Suez Canal University | 2024-08-30 |
| Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma (NCT06438822) | West China Hospital | 2024-08-30 |
| Efficacy of Ra-223 in PSMA PET Optimally Selected Patients (NCT05924672) | University of California, San Francisco | 2024-08-30 |
| A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations (NCT06529419) | AstraZeneca | 2024-08-30 |
| A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (NCT06425302) | Celgene | 2024-08-30 |
| Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs) (NCT06563934) | Xu Yong, MD | 2024-08-30 |
| A Study of Sotorasib in People With Non-Small Cell Lung Cancer (NCT06582771) | Memorial Sloan Kettering Cancer Center | 2024-08-30 |
| Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy (NCT06184516) | University of Florida | 2024-08-30 |
| Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL (NCT06503263) | Navy General Hospital, Beijing | 2024-08-30 |
| Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT06509009) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-08-30 |
| Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib (NCT06445959) | M.D. Anderson Cancer Center | 2024-08-29 |
| LMN-201 for Prevention of C. Difficile Infection Recurrence (NCT05330182) | Lumen Bioscience, Inc. | 2024-08-29 |
| Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. (NCT06440057) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2024-08-29 |
| Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma (NCT06442475) | University of Washington | 2024-08-29 |
| SIALIDASE INHIBITION AS ANTIATHEROSCLEROTIC THERAPY (NCT06590012) | Institute for Atherosclerosis Research, Russia | 2024-08-29 |
| Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats (NCT06501638) | Shanghai East Hospital | 2024-08-29 |
| Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment (NCT06881810) | Central Institute of Mental Health, Mannheim | 2024-08-29 |
| Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease (NCT05785065) | Centre hospitalier de l'Université de Montréal (CHUM) | 2024-08-29 |
| A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease (NCT06557772) | Sanofi | 2024-08-29 |
| Spinal Nalbuphine for Analgesia in Total Hip Arthroplasty (NCT06577155) | Asklepieion Voulas General Hospital | 2024-08-29 |
| Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET (NCT06552429) | Xiamen Amoytop Biotech Co., Ltd. | 2024-08-29 |
| Phase IIa Study Evaluating AZD7798 in Crohn's Disease (NCT06450197) | AstraZeneca | 2024-08-28 |
| Beta-Hydroxybutyrate Feasibility Treating IBD (NCT06351124) | University of Texas at Austin | 2024-08-28 |
| A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery Disease (NCT06717074) | Ribocure Pharmaceuticals AB | 2024-08-28 |
| A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis (NCT06360094) | Boehringer Ingelheim | 2024-08-28 |
| First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) (NCT06351592) | Regeneron Pharmaceuticals | 2024-08-28 |
| A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations (NCT06412198) | M.D. Anderson Cancer Center | 2024-08-28 |
| Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations (NCT06514027) | BeBetter Med Inc | 2024-08-28 |
| KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis (NCT06193889) | Kyverna Therapeutics | 2024-08-28 |
| Phase Ib/IIa Clinical Study of ACC017 Tablets (NCT06719310) | Jiangsu Aidea Pharmaceutical Group Co., Ltd. | 2024-08-28 |
| A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis (NCT06433999) | Priovant Therapeutics, Inc. | 2024-08-28 |
| MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis (NCT06592352) | Clinical Academic Center (2CA-Braga) | 2024-08-27 |
| Volrustomig Priming Regimens Exploratory Phase II Platform Study (NCT06448754) | AstraZeneca | 2024-08-27 |
| Online Tai Chi Plus Fitbit After ACS (NCT05699642) | Beth Israel Deaconess Medical Center | 2024-08-27 |
| Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment (NCT06502977) | Amgen | 2024-08-27 |
| Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. (NCT06617936) | Hua Zhang | 2024-08-27 |
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma (NCT06179888) | National Cancer Institute (NCI) | 2024-08-27 |
| Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer (NCT06559540) | Washington University School of Medicine | 2024-08-27 |